Protocol evaluates antiviral activity against coronaviruses using various cell lines, highlighting cytotoxicity metrics.
The protocol evaluates compounds to determine their antiviral activity against coronaviruses. The antiviral activity is evaluated based on the 50% inhibitory concentration (IC50) and the 50% effective concentration (EC50). Two cell lines can be used for these assays (A549+ACE2+TMP (Invivogen) or VeroE6/TMPRSS2 cells (XenoTech)). The multiplicity of infection (MOI) will depend on the virus stock titer. The incubation time can vary if using a reporter virus. The assay can be performed in 96-well plates (medium throughput screening) or 384-well plates (high throughput screening).
No takes yet. Share an insight, caveat, or question.
Álvarez et al. (2025) studied this question.